Medication guide

Zepbound

tirzepatide

Zepbound is a once-weekly tirzepatide injection labeled for chronic weight management in defined adults and for moderate-to-severe obstructive sleep apnea in adults with obesity. Weight-management and sleep-apnea maintenance doses are not identical.

FDA label revision: February 2026 · Page updated 2026-09-14

What is Zepbound?

How it works

Tirzepatide activates both GIP and GLP-1 receptors. Its effects on incretin signaling influence glucose regulation, appetite, and gastric emptying. The approved purpose, formulation, dose, and monitoring plan depend on this exact brand rather than the ingredient name alone.^[1]

Indications

Adults with obesity, or overweight plus a weight-related condition: Reduce excess body weight and maintain weight reduction long term alongside a reduced-calorie diet and increased physical activity.^[1]
Certain adults with obesity: Treat moderate-to-severe obstructive sleep apnea alongside a reduced-calorie diet and increased physical activity.^[1]

Formulations and dosing

Injection

Subcutaneous · Once weekly

Strengths: 2.5 mg, 5 mg, 7.5 mg, 10 mg, 12.5 mg, 15 mg per dose

Adult dosing

Starting: 2.5 mg once weekly for 4 weeks

Increase to 5 mg once weekly after 4 weeks
If needed, increase in 2.5 mg increments only after at least 4 weeks on the current dose

Maintenance: 5 mg, 10 mg, 15 mg once weekly

Maximum: 15 mg once weekly

^[1]

What Zepbound is not approved for

Zepbound is not labeled to improve glucose control in type 2 diabetes. Mounjaro is the tirzepatide brand with that indication.^[1,2]

Warnings

The label carries a boxed warning about thyroid C-cell tumors in rats. Zepbound is contraindicated with a personal or family history of medullary thyroid carcinoma or MEN 2.^[1]
Severe gastrointestinal reactions can occur, and Zepbound is not recommended in severe gastroparesis.^[1]
Acute pancreatitis has been observed. Persistent severe abdominal pain, with or without vomiting, warrants prompt evaluation.^[1]
Delayed gastric emptying can affect oral medicines and may reduce oral hormonal contraceptive effectiveness after initiation and each dose escalation.^[1]
Rare pulmonary aspiration has been reported during general anesthesia or deep sedation; the procedural team should know Zepbound is being used.^[1]

Contraindications

Personal or family history of medullary thyroid carcinoma, or Multiple Endocrine Neoplasia syndrome type 2.^[1]
Prior serious hypersensitivity reaction to tirzepatide or a Zepbound excipient.^[1]

If a dose is missed

The label says to take a missed dose within 4 days (96 hours). After that, skip it and resume the normal weekly schedule; keep at least 3 days between doses.^[1]

Common adverse reactions

Common reactions include nausea, diarrhea, vomiting, constipation, abdominal pain, indigestion, injection-site reactions, fatigue, hypersensitivity reactions, belching, hair loss, and reflux disease.^[1]

Important label distinctions

The 2.5 mg weekly dose is for initiation, not maintenance. Weight-management maintenance options are 5, 10, or 15 mg weekly; the labeled sleep-apnea maintenance options are 10 or 15 mg weekly.^[1]

Product-specific evidence

In SURMOUNT-1, adults with obesity or overweight and a weight-related condition, without diabetes, had average weight changes at 72 weeks of −15.0%, −19.5%, and −20.9% with tirzepatide 5, 10, and 15 mg, respectively, versus −3.1% with placebo. These are trial averages, not individual promises.^[3]

Cost and coverage

Insurance coverage may depend on the diagnosis, plan formulary, prior-authorization rules, and the exact brand. Before committing to care, confirm the medication cost, clinical or subscription fees, laboratory costs, refill process, and what happens if coverage changes. Prices and coverage should be checked directly rather than assumed from an advertised starting price.

Lifestyle considerations

Medication does not automatically preserve muscle, improve fitness, or meet nutrition needs. A practical plan can include manageable meals, adequate fluid, progressive strength work, aerobic activity, sleep, and follow-up adapted to symptoms and health history. Reduced appetite is not a reason to ignore persistent difficulty eating or drinking.

Questions to ask your clinician

Which Zepbound indication applies: weight management, sleep apnea, or both?
Which maintenance dose fits that indication and my tolerability?
How will sleep-apnea treatment and weight-related outcomes be monitored?
Do oral medicines or planned procedures require special instructions?
What nutrition and strength plan will support function during weight loss?

Sources

Ozempic Wegovy Mounjaro